Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest
Author(s) -
Sebastian Wiberg,
Christian Hassager,
Henrik Schmidt,
Jakob Hartvig Thomsen,
Martin Frydland,
Matias Greve Lindholm,
Dan Eik Høfsten,
Thomas Engstrøm,
Lars Køber,
Jacob Eifer Møller,
Jesper Kjærgaard
Publication year - 2016
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.116.024088
Subject(s) - medicine , exenatide , targeted temperature management , return of spontaneous circulation , neuroprotection , anesthesia , placebo , diabetes mellitus , ischemia , cardiopulmonary resuscitation , pharmacology , resuscitation , type 2 diabetes , endocrinology , alternative medicine , pathology
In-hospital mortality in comatose patients resuscitated from out-of-hospital cardiac arrest (OHCA) is ≈50%. In OHCA patients, the leading cause of death is neurological injury secondary to ischemia and reperfusion. Glucagon-like peptide-1 analogs are approved for type 2 diabetes mellitus; preclinical and clinical data have suggested their organ-protective effects in patients with ischemia and reperfusion injury. The aim of this trial was to investigate the neuroprotective effects of the glucagon-like peptide-1 analog exenatide in resuscitated OHCA patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom